Mesoblast (MESO) Names New Vice Chair
FREE Breaking News Alerts from StreetInsider.com!
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Mesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman
September 1, 2016 6:00 AM EDTNEW YORK and MELBOURNE, Australia, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO) (ASX: MSB) today announced that Mr William (Bill) A. Burns, former Chief Executive Officer (CEO) of Roche Pharmaceuticals, has been appointed Vice Chairman of Mesoblast. In this role, Mr Burns will focus his considerable pharmaceutical industry expertise on activities relating to execution of major strategic partnerships and corporate transactions.
Mr Burns brings to Mesoblast extensive international commercial, business development, and operational experience in the pharmaceutical industry. From 1991-1998, he was Global Head of... More
